In addition, Bruton’s tyrosine kinase inhibitors (BTK) can directly bind to B cells to reduce the overexpression of cytokines caused by BTK signaling, preventing CRS without affecting anti-tumor efficacy (167). Here, BTK is linked to neoplasm.